Previously located in Madison WI at the time of initial SBIR engagement and with strong ties to WARF, Lynx Biosciences is now resident in JLabs San Diego. A clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics with the goal of rapidly advancing drug candidates in oncology and bringing personalized cancer treatments to patients, the firm is organized around developing technologies to enable the prediction of clinical treatment response for multiple myeloma (MM) and other blood cancer patients. Many blood cancers are incurable and standard of care is empirical treatment typically through what is effectively trial and error. With very few actionable technologies to determine an individual patient's response to multiple drugs, the firm's primary product is MicroC3â¢, an assay structured towards analyzing the therapeutic response of MM patientsâ tumor cells with their own non-tumor cells. By incorporating both tumor and non-tumor cells from the bone marrow, MicroC3 provides a more accurate reflection of the unique biology in individual patients that other metho
